Paul Bisaro (NASDAQ: MYGN) adds 7,500 Myriad Genetics shares

Rhea-AI Filing Summary

Myriad Genetics director Paul Bisaro reported an open-market purchase of 7,500 shares of Common Stock at $3.685 per share. After this transaction, he directly holds 97,441 shares. This filing highlights a personal increase in his equity stake in the company.

Insider Trade Summary

Net Buyer: 7,500 shares ($27,638)

Net Buy 1 txn

Insider Bisaro Paul

Role null

Bought 7,500 shs ($28K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	7,500	$3.685	$28K

Holdings After Transaction: Common Stock — 97,441 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 7,500 shares Purchase price: $3.685 per share Post-transaction holdings: 97,441 shares +1 more

4 metrics

Shares purchased 7,500 shares Open-market purchase of Common Stock

Purchase price $3.685 per share Price paid in open-market transaction

Post-transaction holdings 97,441 shares Direct ownership after transaction

Net buy shares 7,500 shares Net change in buy/sell activity

Key Terms

open-market purchase, Common Stock, Form 4, insider transaction

4 terms

open-market purchase financial

"reported an open-market purchase of 7,500 shares of Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"open-market purchase of 7,500 shares of Common Stock at $3.685"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"as disclosed in the Form 4 insider trading report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

insider transaction regulatory

"The Myriad Genetics insider transaction was a buy."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bisaro Paul

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		P		7,500	A	$3.685	97,441	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	By: Justin Hunter For: Paul Bisaro	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Paul Bisaro report for MYGN?

Paul Bisaro reported an open-market purchase of 7,500 Myriad Genetics (MYGN) common shares. He bought them at a price of $3.685 per share, increasing his direct ownership and signaling additional personal exposure to the company’s equity.

At what price did Paul Bisaro buy Myriad Genetics (MYGN) shares?

He bought 7,500 Myriad Genetics shares at $3.685 per share. This open-market purchase price reflects what he was willing to pay to increase his stake, as disclosed in the Form 4 insider trading report.

How many Myriad Genetics (MYGN) shares does Paul Bisaro now own?

After the reported transaction, Paul Bisaro directly owns 97,441 Myriad Genetics common shares. This total includes his new 7,500-share purchase and represents his updated direct equity position as disclosed in the Form 4 filing.

Was the MYGN insider transaction a buy or a sell?

The Myriad Genetics insider transaction was a buy. Director Paul Bisaro executed an open-market purchase of 7,500 common shares, with no accompanying sales reported, resulting in a net increase in his directly held share count.

What does an open-market purchase by a Myriad Genetics director mean?

An open-market purchase means the director bought shares on the public market at prevailing prices. For Myriad Genetics, Paul Bisaro’s purchase of 7,500 shares at $3.685 per share shows he chose to add to his existing direct holdings.